Bryant Fong is a founding General Partner at Biomark Capital, a life sciences private equity fund formed in 2013. Prior to Biomark Capital, Mr. Fong was a Managing Director at Burrill & Company, where he spent almost 16 years investing in and managing investments in private and public companies in the biotechnology industry. Some of Mr. Fong’s notable investments include Pharmasset, Galapagos, Ferrokin Biosciences, Ceptaris Therapeutics, and Novadaq Technologies. Mr. Fong currently serves on the Boards of Directors of a number of private life science companies. Mr. Fong graduated with honors in Biochemistry from the University of California at Berkeley.